Replies to post #352544 on Elite Pharmaceuticals Inc (ELTP)

[WeeZuhl]

Combining the extended release formula and the PEG-based hard shell to form a safe and effective ADF is no slam dunk, especially for a company that failed in 2 tries to get FDA approval for a simple oxyIR bead.

Maybe we could get a quick and easy NDA approval for an abuse-deterrent version of the immediate-release drug, as a proof of concept. Hmmm. Where have I heard this before?